Axsome Therapeutics, Inc.AXSMNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending higher, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-128.68M
↓ 81% below average
Average (9y)
$-71.04M
Historical baseline
Range
High:$-7.46M
Low:$-145.66M
CAGR
+37.2%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-128.68M | +11.7% |
| 2023 | $-145.66M | -24.3% |
| 2022 | $-117.21M | -8.0% |
| 2021 | $-108.53M | -38.3% |
| 2020 | $-78.50M | -69.2% |
| 2019 | $-46.39M | -54.2% |
| 2018 | $-30.09M | -13.6% |
| 2017 | $-26.48M | -23.8% |
| 2016 | $-21.39M | -186.7% |
| 2015 | $-7.46M | - |